193 related articles for article (PubMed ID: 25503169)
1. Radiation recall gastritis secondary to erlotinib in a patient with pancreatic cancer.
Graziani C; Hegde S; Saif MW
Anticancer Res; 2014 Dec; 34(12):7339-43. PubMed ID: 25503169
[TBL] [Abstract][Full Text] [Related]
2. Radiation recall phenomenon secondary to capecitabine: possible role of thymidine phosphorylase.
Saif MW; Black G; Johnson M; Russo S; Diasio R
Cancer Chemother Pharmacol; 2006 Dec; 58(6):771-5. PubMed ID: 16552574
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine-related radiation recall in a patient with pancreatic cancer.
Saif MW; Sellers S; Russo S
Anticancer Drugs; 2006 Jan; 17(1):107-11. PubMed ID: 16317298
[TBL] [Abstract][Full Text] [Related]
4. Radiation recall gastritis secondary to combination of gemcitabine and erlotinib in pancreatic cancer and response to PPI - a case report.
Choi SJ; Kim HJ; Kim JS; Bak YT; Kim JS
BMC Cancer; 2016 Aug; 16():588. PubMed ID: 27484349
[TBL] [Abstract][Full Text] [Related]
5. Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer.
Jiang Y; Mackley HB; Kimchi ET; Zhu J; Gusani N; Kaifi J; Staveley-O'Carroll KF; Belani CP
Cancer Chemother Pharmacol; 2014 Jul; 74(1):205-10. PubMed ID: 24908435
[TBL] [Abstract][Full Text] [Related]
6. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results.
Czito BG; Willett CG; Bendell JC; Morse MA; Tyler DS; Fernando NH; Mantyh CR; Blobe GC; Honeycutt W; Yu D; Clary BM; Pappas TN; Ludwig KA; Hurwitz HI
J Clin Oncol; 2006 Feb; 24(4):656-62. PubMed ID: 16446337
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase.
Saif MW; Black G; Roy S; Bell D; Russo S; Eloubeidi MA; Steg A; Johnson MR; Zelterman D; Diasio RB
Cancer J; 2007; 13(4):247-56. PubMed ID: 17762760
[TBL] [Abstract][Full Text] [Related]
8. Erlotinib in combination with capecitabine (5'dFUR) in resistant pancreatic cancer cell lines.
Chefrour M; Fischel JL; Formento P; Giacometti S; Ferri-Dessens RM; Marouani H; Francoual M; Renée N; Mercier C; Milano G; Ciccolini J
J Chemother; 2010 Apr; 22(2):129-33. PubMed ID: 20435574
[TBL] [Abstract][Full Text] [Related]
9. Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'.
Boeck S; Vehling-Kaiser U; Waldschmidt D; Kettner E; Märten A; Winkelmann C; Klein S; Kojouharoff G; Gauler T; Fischer von Weikersthal L; Clemens MR; Geissler M; Greten TF; Hegewisch-Becker S; Neugebauer S; Heinemann V
Anticancer Drugs; 2010 Jan; 21(1):94-100. PubMed ID: 19770635
[TBL] [Abstract][Full Text] [Related]
10. Gastrointestinal bleeding associated with concurrent capecitabine and radiotherapy in patients with pancreatic cancer.
Saif MW; Moody JS; Russo SM
JOP; 2005 Jul; 6(4):325-33. PubMed ID: 16006682
[TBL] [Abstract][Full Text] [Related]
11. [Chemotherapy for pancreatic cancer].
Kim YT
Korean J Gastroenterol; 2008 Feb; 51(2):111-8. PubMed ID: 18349573
[TBL] [Abstract][Full Text] [Related]
12. Long-term results of full-dose gemcitabine with radiation therapy compared to 5-fluorouracil with radiation therapy for locally advanced pancreas cancer.
Huang J; Robertson JM; Margolis J; Balaraman S; Gustafson G; Khilanani P; Nadeau L; Jury R; McIntosh B
Radiother Oncol; 2011 May; 99(2):114-9. PubMed ID: 21621866
[TBL] [Abstract][Full Text] [Related]
13. Challenges of drug resistance in the management of pancreatic cancer.
Sheikh R; Walsh N; Clynes M; O'Connor R; McDermott R
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1647-61. PubMed ID: 20942635
[TBL] [Abstract][Full Text] [Related]
14. Erlotinib or capecitabine with gemcitabine in pancreatic cancer?
de Jager J; Stebbing J
Future Oncol; 2006 Apr; 2(2):161-3. PubMed ID: 16563084
[No Abstract] [Full Text] [Related]
15. Gemcitabine-related radiation recall preferentially involves internal tissue and organs.
Friedlander PA; Bansal R; Schwartz L; Wagman R; Posner J; Kemeny N
Cancer; 2004 May; 100(9):1793-9. PubMed ID: 15112258
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer.
Wu Z; Gabrielson A; Hwang JJ; Pishvaian MJ; Weiner LM; Zhuang T; Ley L; Marshall JL; He AR
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1309-14. PubMed ID: 26507197
[TBL] [Abstract][Full Text] [Related]
17. Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer.
Makris D; Scherpereel A; Copin MC; Colin G; Brun L; Lafitte JJ; Marquette CH
BMC Cancer; 2007 Aug; 7():150. PubMed ID: 17683587
[TBL] [Abstract][Full Text] [Related]
18. Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer.
Boeck S; Hausmann A; Reibke R; Schulz C; Heinemann V
Anticancer Drugs; 2007 Oct; 18(9):1109-11. PubMed ID: 17704662
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.
Ouchi KF; Yanagisawa M; Sekiguchi F; Tanaka Y
Cancer Chemother Pharmacol; 2006 May; 57(5):693-702. PubMed ID: 16362295
[TBL] [Abstract][Full Text] [Related]
20. Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects.
Blanquicett C; Saif MW; Buchsbaum DJ; Eloubeidi M; Vickers SM; Chhieng DC; Carpenter MD; Sellers JC; Russo S; Diasio RB; Johnson MR
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8773-81. PubMed ID: 16361565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
